Volume | 36,141 |
|
|||||
News | - | ||||||
Day High | 141.26 | Low High |
|||||
Day Low | 139.41 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
DaVita Inc | DVA | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
140.92 | 139.41 | 141.26 | 140.93 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,137 | 36,141 | $ 140.63 | $ 5,082,520 | - | 71.51 - 145.84 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
10:09:51 | 5 | $ 139.6398 | USD |
DaVita (DVA) Options Flow Summary
DaVita Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
12.39B | 87.70M | - | 12.14B | 691.54M | 7.89 | 17.91 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
DaVita News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DVA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 136.94 | 141.435 | 135.7075 | 138.66 | 670,752 | 2.68 | 1.96% |
1 Month | 133.01 | 145.84 | 130.96 | 137.47 | 891,806 | 6.61 | 4.97% |
3 Months | 124.53 | 145.84 | 124.42 | 135.11 | 797,186 | 15.09 | 12.12% |
6 Months | 97.44 | 145.84 | 97.31 | 120.50 | 854,410 | 42.18 | 43.29% |
1 Year | 100.33 | 145.84 | 71.51 | 104.97 | 902,295 | 39.29 | 39.16% |
3 Years | 122.92 | 145.84 | 65.28 | 100.23 | 800,380 | 16.70 | 13.59% |
5 Years | 49.10 | 145.84 | 43.40 | 86.30 | 1,052,852 | 90.52 | 184.36% |
DaVita Description
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government ( primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business. |